๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Colony-stimulating factors in the clinic

โœ Scribed by Nydia G. Testa; T.Michael Dexter

Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
666 KB
Volume
3
Category
Article
ISSN
0958-1669

No coin nor oath required. For personal study only.

โœฆ Synopsis

Recombinant purified human haemopoietic growth factors are available for clinical trials and some have been licensed for therapeutic use. Some haemopoietic lineages (erythroid, neutrophilic, monocyte-macrophagic) can be selectively stimulated in order to ameliorate the cytopenias that follow cytotoxic treatment, or that characterize some haematological syndromes, and to stimulate mature cell function. Advances in the knowledge of receptor-ligand interactions and of transduction mechanisms, plus the production of synthetic or mutant molecules that may mimic, potentiate or antagonize the effects of the natural growth factors, should make novel therapeutic approaches possible.

๐Ÿ“œ SIMILAR VOLUMES

The use of colony stimulating factors in
The use of colony stimulating factors in clinical bone marrow transplantation
โœ Robert S Negrin; Peter L Greenberg ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 508 KB

The use of colony stimulating factors in clinical bone marrow transplantation is rapidly evolving. Both granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor have shown efficacy in bone marrow transplant patients in accelerating the rate of myeloid recovery. The

A phase I clinical and pharmacologic stu
A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
โœ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB ๐Ÿ‘ 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist

Hemopoietic colony-stimulating factors
Hemopoietic colony-stimulating factors
โœ Nicos A. Nicola; Mathew Vadas ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 583 KB
The use of colony stimulating factors in
The use of colony stimulating factors in combination
โœ Malcolm A.S. Moore ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 995 KB

More gene products that influence hematopoiesis continue to become available. As a result, is now possible to carry out both in vivo and in vitro studies with purified erythropoietin, various colony stimulating factors and 11 interleukins. The identification and availability of the ligand for the c-